Organization (Industry)
Ascentage Pharma Group Inc. (United States)
ClinicalTrials.gov lists Ascentage Pharma Group Inc. (United States) as lead sponsor of 53 trials. It has 102 active development programs and 16 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers Ascentage Pharma Group Inc. (United States): 53 lead-sponsored trials and 1 legal-entity registration. Part of ASCENTAGE PHARMA GROUP INTERNATIONAL.
Disease areas (56)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 8 |
| Lymphoma | 8 |
| Lymphoma, Non-Hodgkin | 7 |
| Leukemia, Myeloid, Acute | 5 |
| Hematologic Neoplasms | 4 |
Showing 5 of 56 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 7 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 9 |
| 2020 | 10 |
| 2019 | 9 |
| 2018 | 4 |
| 2017 | 3 |
Showing 10 of 11 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 30 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 17 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (102)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Lisaftoclax | Leukemia, Myeloid, Acute | Phase 3 | 2 |
| Olverembatinib | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 3 | 5 |
| Olverembatinib | Leukemia, Myeloid, Chronic-Phase | Phase 3 | 4 |
| Investigator's choice of TKI | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 3 | 1 |
| Bosutinib | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 3 | 1 |
Showing 5 of 102 active programs.
Approved assets (16)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| RITUXIMAB | 2 |
| Chlorambucil | 1 |
| Bosutinib | 1 |
| ACALABRUTINIB | 1 |
| FLUDARABINE | 1 |
Showing 5 of 16 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 47% hit target (n=17) | 12% on time (n=17) |
Journals published in (8)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMC cancer | 1 |
| Cancer cell international | 1 |
| Cell reports. Medicine | 1 |
| EClinicalMedicine | 1 |
| JAMA oncology | 1 |
Showing 5 of 8 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 30 | 30 | 2025-07-29 |
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Suzhou Yasheng Pharmaceutical Co., Ltd. | Co sponsors trial with | 7 |
| HealthQuest Pharma Inc. | Co sponsors trial with | 4 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 3 |
| Guangzhou Healthquest Pharma Co., Ltd | Co sponsors trial with | 1 |
Latest dated events (88)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 88 events.
Biomarker capability evidence (302)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 302 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.